Iowa City, Iowa -University of Iowa Health Care is taking part in the Phase 3 clinical trial for the new Novavax COVID-19 vaccine.
The medical center is enrolling 250 people to test the vaccine for its rate of success and safety.
Participants will get two doses, and one-third of them will receive a placebo in the trial.
University of Iowa Health Care previously took part in the clinical trial for the Pfizer vaccine, which is now being administered across the nation.
Novavax uses a more traditional vaccine technology than the Pfizer and Moderna vaccines, which use mRNA to generate an immune response.
Iowa City, Iowa -University of Iowa Health Care is taking part in the Phase 3 clinical trial for the new Novavax COVID-19 vaccine.
The medical center is enrolling 250 people to test the vaccine for its rate of success and safety.
Participants will get two doses, and one-third of them will receive a placebo in the trial.
University of Iowa Health Care previously took part in the clinical trial for the Pfizer vaccine, which is now being administered across the nation.
Novavax uses a more traditional vaccine technology than the Pfizer and Moderna vaccines, which use mRNA to generate an immune response.
By Sue Danielson
Jan 8, 2021
(Iowa City, IA) University of Iowa Health Care is taking part in COVID-19 vaccine trial. Researchers are testing a vaccine by Novavax. The multi-site clinical trial aims to enroll 30-thousand people, 250-in Iowa. Participants will get two doses of the vaccine, 21-days apart.
“Different types of vaccines are helpful
because certain people might respond better to one type of vaccine than another,” says Patricia Winokur, MD, executive dean of the University of Iowa Carver College of Medicine, and principal investigator for the UI trial site for the Novavax vaccine. Winokur also led the UI site for the clinical trial of the Pfizer-BioNTech vaccine.
By Sue Danielson
Jan 8, 2021
(Iowa City, IA) University of Iowa Health Care is taking part in COVID-19 vaccine trial. Researchers are testing a vaccine by Novavax. The multi-site clinical trial aims to enroll 30-thousand people, 250-in Iowa. Participants will get two doses of the vaccine, 21-days apart.
“Different types of vaccines are helpful
because certain people might respond better to one type of vaccine than another,” says Patricia Winokur, MD, executive dean of the University of Iowa Carver College of Medicine, and principal investigator for the UI trial site for the Novavax vaccine. Winokur also led the UI site for the clinical trial of the Pfizer-BioNTech vaccine.
12/28/20
Officials at University of Iowa Health care are participating in a trial for a new COVID-19 vaccine.
The Hospitals and Clinics were a trial site for the Pfizer-BioNTech vaccine earlier this year; the new vaccine comes from Novavax.
The Cedar Rapids Gazette reports that the Novavax vaccine is much more like a traditional vaccine, using technology that developed the current flu vaccines. It will also require two doses, three weeks apart like the Pfizer vaccine.
The UIHC will be recruiting about 250 participants for the trial, aged 18 and older. UIHC Executive Dean Patricia Winokur told the Gazette that researchers are specifically interested in recruiting people at high risk for severe COVID-19 infection, underrepresented populations, and front-line workers.